Gravity Analytica

IN8bio to Present at Biotech Showcase 2025 in San Francisco

INAB 01.06.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:Biotech Showcase

Full Press Release SEC Filings Our INAB Tweets

About Gravity Analytica

Recent Filings

12.23.2024 - 4 Statement of changes in beneficial ownership of securities

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) --IN8bio, Inc.(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below.

Biotech Showcase, January 13 - 15, 2025

Panel: The Battle Against Cancer: The Armamentarium Keeps Expanding

Date: Monday, January 13, 2025
Time: 8:00 AM PT
Track: Yosemite C (Ballroom Level)

Corporate presentation

Date: Tuesday, January 14, 2025
Time: 2:00 PM PT
Track: Yosemite A (Ballroom Level)
Live webcast:https://event.webcasts.com/starthere.jsp?ei=1703689&tp_key=9d7f185675

Interested parties can register to attend the event here: https://informaconnect.com/biotech-showcase/registration-options/

Additionally, IN8bio management will be in San Francisco from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference and will be available for meetings with investors. Individuals interested in meeting with IN8bio management can contactgdschulman@in8bio.com.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visitwww.IN8bio.com.

Investors & Company Contacts

Glenn Schulman, PharmD, MPH203.494.7411gdschulman@in8bio.com

IN8bio, Inc.Patrick McCall646.933.5603pfmccall@IN8bio.com

Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com